Back to News
Market Impact: 0.15

Detailed Fundamental Analysis

VYMNDAQ
Company FundamentalsCapital Returns (Dividends / Buybacks)Analyst InsightsHealthcare & Biotech
Detailed Fundamental Analysis

Validea's fundamental report on the Vanguard High Dividend Yield ETF (VYM), a Large-Cap Multi-Factor ETF, details its factor exposures and portfolio composition. VYM's largest sector holding is Financials, with Biotechnology & Drugs as its top industry. The ETF exhibits strong exposure to Low Volatility with a score of 89, complemented by scores of 71 for Value, 66 for Quality, and 63 for Momentum, indicating its primary characteristic as a low-volatility, high-dividend investment vehicle.

Analysis

The Vanguard High Dividend Yield ETF (VYM) is a Large-Cap Multi-Factor fund characterized primarily by its extremely high exposure to the Low Volatility factor, scoring 89 out of 99. This defensive tilt is complemented by a significant orientation towards Value (71) and Quality (66), indicating that its portfolio consists of fundamentally sound companies trading at reasonable valuations. The Momentum score is moderate at 63, suggesting the ETF does not primarily chase trending stocks, which aligns with its conservative profile. Portfolio construction shows a notable concentration in the Financial sector, and more specifically, the Biotechnology & Drugs industry, which represents its largest single industry holding. This composition suggests VYM is engineered to provide income and relative stability rather than aggressive growth, appealing to investors with a lower risk appetite.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.00

Ticker Sentiment

NDAQ0.00
VYM0.10

Key Decisions for Investors

  • Given its high Low Volatility score of 89 and solid Value exposure, VYM should be considered by investors seeking to add a defensive, income-generating component to their portfolios, particularly as a hedge against market volatility.
  • Investors must be aware of the ETF's significant concentration in the Financials and Biotechnology & Drugs sectors, and should assess how this specific sector risk fits within their overall asset allocation.
  • The moderate Momentum score of 63 suggests the ETF may lag the broader market during strong, growth-led rallies, but its factor profile is positioned for potential outperformance and capital preservation during market corrections or downturns.